Eli Lilly and Company (LLY)

Eli Lilly announced its acquisition of Merida Biosciences for up to US$2.88 billion, aiming to expand its immunology portfolio with a focus on autoimmune conditions like Graves’ disease and thyroid eye disease. Merida's lead drug candidate, MER511, is in early development and targets thyroid-stimulating antibodies. This move signifies Lilly's strategy to diversify its pipeline beyond its successful weight-loss drugs.

Bristol Myers Squibb (BMY) presented five-year data for Camzyos at the European Society of Cardiology Congress, demonstrating sustained efficacy and consistent improvements for obstructive hypertrophic cardiomyopathy (oHCM) patients. Real-world evidence corroborated safety, aligning with clinical trials and solidifying Camzyos's position as a key cardiac myosin inhibitor. This data reinforces Bristol Myers Squibb's cardiovascular strategy and its ability to manage patent pressures with strong late-stage pipeline assets.

The FDA has approved Eli Lilly's Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events, including heart attack, stroke, or cardiovascular death, in adults with type 2 diabetes who are at high risk for these events. This approval makes Mounjaro the first and only GIP and GLP-1 receptor agonist with this indication, based on results from the SURPASS-CVOT trial, which compared it head-to-head with Trulicity. Mounjaro is already approved for improving blood sugar and has established benefits in A1C and weight loss.

Incyte (INCY) shares have risen 0.8% since its last earnings report, underperforming the S&P 500. The company reported strong Q2 2026 results with earnings and revenues beating estimates, driven by sales of Jakafi and Opzelura, leading to raised 2026 guidance. However, analyst estimates have trended downward, and the stock currently holds a Zacks Rank #3 (Hold).

Eli Lilly and Co (LLY) stock opened down 3.57% on August 26, primarily due to investor profit-taking after a recent surge and growing concerns over reimbursement for obesity treatments. Despite this short-term pressure, the company maintains a strong competitive position and a positive long-term growth outlook in the cardiometabolic space. Key risks include employer coverage pushback, commercial hurdles for oral GLP-1 drugs, and European reimbursement pressures.